TC BioPharm to Outsource Production

• TC BioPharm is shifting to a contract development and manufacturing organisation (CDMO) model, reducing its in-house production workforce by 50%.

• The move is expected to cut operational costs by 55%, saving $4.2 million annually.

TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company, has announced plans to transition to a more decentralised model by outsourcing several functions. This shift includes moving to a CDMO model for production to support larger-scale manufacturing for future clinical trials. As a result, the company will reduce its workforce by approximately 20 employees, representing half of its total headcount.

The transition will allow TC BioPharm to explore new manufacturing facilities incorporating automated and advanced cell therapy production technologies. Additionally, the company is reviewing alternative approaches for testing and clinical requirements, aligning with a decentralised drug development strategy. The workforce reductions, primarily affecting production and quality divisions, are expected to be completed by the end of Q2 2025.

Cost savings are a key factor in this restructuring. The company anticipates reducing its core operational expenses by 55% compared to 2024, with estimated savings of $2.1 million in 2025 and an annualised reduction of approximately $4.2 million.

“This decision to reduce staff is attributable to the company’s strategic shift in focus towards an outsourced production model and something that we believe will ultimately better position TC BioPharm for future clinical trial plans as well as advancements in new cell therapy manufacturing technologies,” said Bryan Kobel, CEO of TC BioPharm.

The company’s strategic overhaul comes as it prepares for the review of ACHIEVE trial data, which will inform its next clinical pathway. By streamlining operations and focusing on external partnerships, TC BioPharm aims to strengthen its foundation for future growth.